31 October 2014, Brussels – The last month has been extremely eventful for EPHA and the public health community with the European Parliament hearings of the new Commission and, of course, the campaign for pharmaceuticals and medical devices to stay in the health directorate. We were thrilled to see the way Commissioner-designate Andriukaitis handled his hearing and the vote of confidence from the EP that paved the way for him to become the Commissioner for Health and Safety. We are looking forward to an excellent working relationship with the new Directorate and strong leadership from (the soon to be) Commissioner Andriukaitis.
—-
To better understand how some Commissioners will address the health dimension of their portfolios, EPHA produced a series of Commissioners profiles.
—–
EPHA and our advocacy partners led the European public health community in an advocacy campaign to persuade Mr Juncker, the European Commission’s President-elect, not to put commercial interests before health and change his decision to move pharmaceutical and health technology policy from the health directorate to industry and internal market. For a while, we thought that joint efforts with the EP and several Member States had been successful, yet it soon emerged that Mr Juncker had not been entirely precise about medical devices and health technologies and at the time of writing we are still waiting for official confirmation of his final decision: will they be regulated as health products or as any other commercial good? Interestingly, it is not only the civil society that has been left in the dark – in a joint press release with EPHA, Members of the European Parliament (MEPs) showed their concern about the ambiguity of Mr Juncker’s statement.
This month the European Commission’s High Level Group on Administrative Burdens (also known as the Stoiber Group) published its final report pushing for a deregulatory agenda. As Peggy Maguire, EPHA President (EPHA was represented on the Stoiber group by the previous Secretary General) said: “It is extraordinary that while austerity is pushing democracy and European legitimacy to the brink, there are people still intent on defending the de-regulatory status quo with little regard for the greater public interest. ‘Soft’ voluntary measures do little if anything for public health. Regulation promotes innovation where we need it most.”
Amidst all of the attention on the new Commission, the European Parliament voted against ending EU subsidies to tobacco crops. While on the one hand there are many MEPs supportive of legislating in favour of health with regards to pharmaceutical products, it seems that over half of the European Parliament is happy to continue pumping taxpayer’s money to a harmful industry instead of supporting farmers to make the shift to healthier and more sustainable crops as part of a new CAP fit for today’s challenge.
At the beginning of the month EPHA wrote to Ministers responsible for trade and finance in Europe to support for the Scottish Minimum Unit Pricing for Alcohol (MUP) case currently being considered in the ECJ. In 2012 the Scottish Government passed legislation to introduce MUP to tackle the problems caused by cheap alcohol. Yet, the Scotch Whisky Association (SWA) and other European wine and spirits producers took action against the proposal claiming that it breaches the UK’s EU treaty obligations. If successful for the Scottish Government, this has the potential to be a landmark case for public health.
Tomorrow Juncker’s College of Commissioners will take over from Barroso’s team with the challenge of regaining the trust lost in the European project shown by voters last spring. The goal of smart, sustainable, and inclusive growth that meets the needs of the people must top Mr Juncker’s to-do list for the next five years.
This is my last EPHA newsletter at EPHA’s interim Secretary General. It has been an incredible few months that saw us through the General Assembly, Annual Conference, fundraising and the daily management of the Secretariat. The Secretariat is looking forward to welcoming Nina Renshaw, the new Secretary General, on the 17th of November, and I will be changing roles to focus on strategic partnerships and development devoting my time to finding ways to ensure EPHA’s financial sustainability.
Emma Woodford – Interim Secretary General
——-
——-
Read all the online articles from our October 2014 Newsletter
——–
——–
Other highlights from previous weeks:
– Save the date] [Launch of HEPAMAP research roadmap
– EPHA 2014 Annual Conference – video interviews with key speakers
– Updated Briefing notes] [The impact of the economic crisis on public health
– EPHA contributes to joint civil society consultation response on Europe 2020 Review
– EPHA response to Public Consultation on Europe 2020 Strategy Mid-Term Review
